GSK: agreement to acquire IDRx
(CercleFinance.com) - GSK has announced an agreement to acquire IDRx, a Boston-based clinical-stage biopharmaceutical company dedicated to the development of precision therapies for the treatment of gastrointestinal stromal tumors (GIST).
Under the terms of the agreement, the British pharmaceutical company will initially pay $1bn, with the possibility of an additional milestone payment of $150m, based on successful regulatory approval.
IDRx's lead molecule, IDRX-42, offers the potential to address all key KIT mutations in TSGI that drive tumor growth and progression, and improves tolerability, as well as gaps in current treatments.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
Under the terms of the agreement, the British pharmaceutical company will initially pay $1bn, with the possibility of an additional milestone payment of $150m, based on successful regulatory approval.
IDRx's lead molecule, IDRX-42, offers the potential to address all key KIT mutations in TSGI that drive tumor growth and progression, and improves tolerability, as well as gaps in current treatments.
Copyright (c) 2025 CercleFinance.com. All rights reserved.